After Mizuho Securities and Canaccord Genuity assigned a Buy rating to Aerie Pharma in the last month, the company received another Buy, this time from H.C. Wainwright. Analyst Oren Livnat reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI) today and set a price target of $78. The company’s shares closed yesterday at $49.95.
Livnat wrote:
“Exchange NASDAQ Value (M) $1,754.0 Market Cap (M) $1,963 Public Market Float (M) 21.6 Shares Outstanding (M) 39.3 3 Interest (M) 5.77 Cash (M) $334.0 Total Debt (M) $125.0 Year – (0.03) FY (3.37) (3.63) (1.90) Year – 43.1 FY 0.0 18.9 97.9 70 60 50 40 30 0 Vol. (mil) Price Rhopressa just launched; commence prescription data gazing.”
According to TipRanks.com, Livnat is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -10.5% and a 29.4% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Currently, the analyst consensus on Aerie Pharma is Strong Buy and the average price target is $81.75, representing a 63.7% upside.
In a report issued on April 30, Mizuho Securities also maintained a Buy rating on the stock with a $77 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $66.60 and a one-year low of $38.23. Currently, Aerie Pharma has an average volume of 310.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates are Rhopressa and Roclatan.
